Tag: Parkinson’s

Ireland to Launch Research for Better Understanding of Parkinson’s

A new research study aims to deepen the understanding of Parkinson’s so that better treatments can be developed in the future. The project, which will be coordinated by RCSI, has been awarded €7m by t...

Servier and Oncodesign Team Up for R&D Parkinson’s Drug

Servier, an international pharmaceutical company governed by a non-profit foundation, and biopharmaceutical company, Oncodesign have announced a strategic partnership for the research and development ...

Zydus Cadila Announced First Approval for Transdermal Product in US

Zydus Cadila has received the approval from the USFDA to market Rivastigmine Transdermal System (US RLD – EXELON® PATCH), 4.6 mg/24 hrs, 9.5 mg/24 hrs and 13.3 mg/24 hrs, marking its first approval fo...

FDA Rejected Sunovion’s Parkinson’s Drug

The U.S. Food and Drug Administration (FDA) rejected Sunovion Pharmaceuticals’ experimental treatment for OFF episodes of Parkinson’s disease. The regulatory agency issued a Complete Response Lette...

Generic for Alzheimer’s and Parkinson’s Approved by FDA

The U.S. Food and Drug Administration (FDA) approved Bridgewater, NJ-based Amneal Pharmaceuticals’ generic version of Novartis’ Exelon Patch (Rivastigmine Transdermal System) for dementia related to A...

Acorda’s Drug for Parkinson’s and OFF Episodes Approved by FDA

Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that the U.S. Food and Drug Administration approved INBRIJA™ for intermittent treatment of OFF episodes in people with Parkinson’s disease treated wit...